189 related articles for article (PubMed ID: 20180805)
1. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Mukohara T; Nakajima H; Mukai H; Nagai S; Itoh K; Umeyama Y; Hashimoto J; Minami H
Cancer Sci; 2010 Apr; 101(4):963-8. PubMed ID: 20180805
[TBL] [Abstract][Full Text] [Related]
2. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
3. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Fujiwara Y; Kiyota N; Chayahara N; Suzuki A; Umeyama Y; Mukohara T; Minami H
Invest New Drugs; 2012 Jun; 30(3):1055-64. PubMed ID: 21301929
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Fruehauf J; Lutzky J; McDermott D; Brown CK; Meric JB; Rosbrook B; Shalinsky DR; Liau KF; Niethammer AG; Kim S; Rixe O
Clin Cancer Res; 2011 Dec; 17(23):7462-9. PubMed ID: 21976544
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
6. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri TK
Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
[TBL] [Abstract][Full Text] [Related]
14. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
[TBL] [Abstract][Full Text] [Related]
16. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
17. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
[TBL] [Abstract][Full Text] [Related]
20. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
